HCPLive Network

Phase 3 Trial of Experimental Gout Drug Lesinurad to Begin

Phase 3 Trial of Experimental Gout Drug Lesinurad to BeginArdea Biosciences announced on Monday that it would soon begin the first of four planned Phase 3 clinical trials of its experimental gout drug lesinurad. The trial is expected to include around 2,000 gout patients at study sites around the world.
 
Lesinurad is an oral inhibitor of the URAT1 transporter in the kidney that regulates uric acid excretion. According to a press release from Ardea Biosciences, around 90% of gout patients are thought to excrete too little uric acid, and studies have found that defective renal transporters, which promote excretion of uric acid under normal circumstances, are genetically linked to gout.
 
Since currently available gout drugs such as the xanthine oxidase inhibitors allopurinol and febuxostat have a mechanism of action different from URAT1 inhibitors, the hope is that lesinurad will be able to be used in conjunction with these other drugs to help the many gout patients who are not adequately treated with existing therapies alone. In previous Phase 1 and 2 trials, lesinurad has been tested on over 700 patients as a single agent and in combination with allopurinol and febuxostat.

Further Reading
Recent pharmaceutical studies show work in helping patients with high blood pressure and elevated cholesterol levels.
For patients diagnosed with osteoarthritis, daily activities that many people take for granted, including sleep, can be interrupted or difficult, often causing psychological challenges as well.
Daily aspirin use, even at low doses, may reduce mortality among men with high-risk nonmetastatic prostate cancer, according to research published online Oct. 20 in the Journal of Clinical Oncology.
Targets of workplace bullying can offer chaos, report, or quest narratives about their experiences, and coworker response plays a role in narrative development, according to a study published online Sept. 25 in Management Communication Quarterly.
The US health care system ranks last compared to other industrialized nations when it comes to affordability and patient access, according to a new survey published in the Oct. 23 issue of the New England Journal of Medicine.
Monika Fischer, MD, discusses the outcomes of a study assessing fecal microbiota transplantation for c. difficile infection at the 2014 ACG Annual Scientific Meeting in Philadelphia, PA.
For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab improves outcome versus fluorouracil, leucovorin, and irinotecan plus bevacizumab, according to a study published in the Oct. 23 issue of the New England Journal of Medicine.
More Reading